CALM: 24-month retinal thickness outcomes from a real-world registry study of patients with chronic non-infectious uveitis affecting the posterior segment treated with the 0.18 mg fluocinolone acetonide intravitreal implant

被引：0

作者：

Lin, Phoebe ^{[1
]}

Suhler, Eric B. ^{[2
]}

机构：

[1] Cleveland Clin, Dept Ophthalmol, Cleveland, OH USA

[2] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR USA

来源：

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2024年 / 65卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

6454

引用

页数：2

共 35 条

[1] CALM: 24-month safety outcomes from a real-world registry study of patients with chronic non-infectious uveitis affecting the posterior segment treated with the 0.18 mg fluocinolone acetonide intravitreal implant
Begaj, Tedi
Faia, Lisa
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
[2] CALM: A retrospective registry to characterize clinical outcomes for chronic non-infectious posterior segment uveitis patients treated with the 0.18 mg fluocinolone acetonide intravitreal implant: Retinal Anatomical Outcomes
Zhao, Alison
Seth, Kanika
Bena, James
Morrison, Shannon
Singh, Rishi
Sharma, Sumit
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
[3] CALM: 12-month results from a real-world registry to characterize clinical outcomes for patients with chronic non-infectious posterior segment uveitis treated with a 0.18 mg fluocinolone acetonide intravitreal insert
Anesi, Stephen
Chang, Peter
Singh, Rishi
Sharma, Sumit
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
[4] CALM: A retrospective registry to characterize clinical outcome data for chronic non-infectious posterior segment uveitis patients treated with a 0.18 mg fluocinolone acetonide intravitreal insert
Seth, Kanika
Singh, Rishi P.
Sharma, Sumit
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
[5] CALM: A retrospective registry to characterize clinical outcomes for chronic non-infectious posterior segment uveitis patients treated with the 0.18 mg fluocinolone acetonide intravitreal insert: Intraocular Pressure and Safety Data Analysis
Seth, Kanika
Zhao, Alison
Singh, Rishi
Sharma, Sumit
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
[6] The effectiveness of the 0.19 mg fluocinolone acetonide implant in treating non-infectious posterior uveitis: a real-world experience
Kozak, Igor
Gurbaxani, Avinash
Pandova, Maya
JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION, 2024, 14 (01):
[7] Controlling Posterior Segment Uveitic Recurrences: Results from a Phase 3 Study of 0.18 mg Fluocinolone Acetonide Intravitreal Insert (FAi) in Subjects with Chronic Non-Infectious Uveitis Affecting the Posterior Segment
Quan Dong Nguyen
Patel, Keyur
Paggiarino, Dario A.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
[8] Fluocinolone Acetonide Implant for Patients suffering from chronic posterior non-infectious Uveitis
Bitzer, Michaela
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2019, 236 (07) : 841 - 841
[9] Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis
Carlos Pavesio
Carsten Heinz
Eye, 2022, 36 : 1231 - 1237
[10] Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis
Pavesio, Carlos
Heinz, Carsten
EYE, 2022, 36 (06) : 1231 - 1237

← 1 2 3 4 →